Furthermore, murine colon cancer studies by Mukerjee et al. have shown that the vaccination of MHC (major histocompatibility complex) class I restricted cell surface-associated mucin (MUC1) peptide combined with ODN elicited a stronger anti-tumor response compared with MUC1 peptide alone [18]. Here, MUC1 is linked to malignant colon neoplasm.